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Introduction
============

Squamous cell carcinoma of the head and neck is a significant contributor to worldwide morbidity and mortality. There are more than 500,000 new cases worldwide reported annually \[[@REF1]\]. Laryngeal squamous cell carcinoma (LSCC) is the second most common head and neck malignancy worldwide with 151,000 new cases per year worldwide \[[@REF2]-[@REF3]\]. While there is a great amount of evidence that suggests alcohol and tobacco are causative agents in developing LSCC, there are increasing incidences of LSCC in non-smokers and non-drinkers \[[@REF4]-[@REF6]\].

There is great variation in reporting the incidence of HPV-positive LSCC in literature, however, a recent meta-analysis reports incidence at roughly 25% with minor variation depending on methods of testing \[[@REF7]\]. While it is regarded that HPV-positive oropharyngeal squamous carcinoma has better survival outcomes, there is no evidence the same holds true for LSCC.

The aim of this study is to conduct a systematic review and meta-analysis to evaluate and quantify the effect of human papillomavirus (HPV) on survival outcome of LSCC and to assess regional variation across the globe.

Materials and methods
=====================

Search strategy and selection criteria:

Using the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines, this study was conducted \[[@REF8]\]. Electronic search of Medline, Embase, Cochrane Methodology Register, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, Database of Abstracts of Reviews and Effectiveness, ACP Journal Club, and NHS Economic Evaluation Database was conducted from their respective conception to January 2017.

Utilising both MeSH terms and keywords, the search was conducted to ensure ideal sensitivity. The terms "larynx", "squamous cell carcinoma" and "human papilloma virus (HPV)" along with their relevant variations were used. Relevant studies were identified by two independent reviewers (Na.A. and Ni.A.) and were extracted for further evaluations.

Inclusion criteria included histologically confirmed LSCC and HPV-DNA or p16 status was confirmed by polymerase chain reaction (PCR), immunohistochemistry (IHC), and/or in-situ hybridization (ISH). Studies were excluded if they did not provide overall survival (OS) or disease-free survival (DFS) comparing HPV-positive and HPV-negative LSCC. Search was limited to papers with minimum length of follow up of one year, English language, and human subjects. Abstracts, case-reports, conference presentation and any papers without original data were excluded.

Data extraction and critical appraisal:

Two independent investigators (Na.A. and Ni.A.) extracted data, with discrepancies between reviewers resolved by consensus. The senior investigators (N.S. and R.C.) reviewed final results.

Statistical analysis:

Meta-analysis was performed with Review Manager (Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) using pooled OS and DFS of HPV-positive and HPV-negative LSCC \[[@REF9]\]. Data was pooled using the DerSimionian and Laird's random effect model at one, two, three, four, and five years post-diagnosis \[[@REF10]\]. To assess publication bias, Egger's linear regression test was utilized and heterogeneity was assessed and quantified using the I^2^ statistics to measure percentage variability among summary indices \[[@REF11]-[@REF12]\]. Statistical significance was set at 0.05.

Results
=======

Through the search of the nine databases, 1214 studies were identified. After excluding studies with duplicated cohorts, irrelevant studies, and studies with data not extractable, 14 studies were analyzed for statistical analysis. All the studies were case-control with two prospective studies, while the remaining 12 were retrospective. Bias was assessed using Egger's test for publication bias and no publication bias was identified \[[@REF11]\]. PRISMA guideline study selection is shown in Figure [1](#FIG1){ref-type="fig"}, with a description of studies in Table [1](#TAB1){ref-type="table"}.
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###### Description of Studies Utilized in this Meta-analysis.

NR -- not recorded, ISH -- In-situ hybridization, PCR -- polymerase chain reaction, IHC -- Immunohistochemistry, PE -- paraffin embedded, FF -- fresh frozen

  ------------- ------ ------------------- ----- --------------- -------------- --------------- ------------------ -------- ----- ---------
  Author        Year   Country             n     Study Period    Study Design   Prospective     Detection of HPV   Sample   p16   HPV DNA
  Rivera-Pena   2016   USA (Puerto Rico)   83    1993-2005       Case-control   Retrospective   PCR                FF       NR    Y
  Hernandez     2016   USA                 101   1993-2004       Case-control   Retrospective   IHC                PE       Y     NR
  Atighechi     2016   Iran                44    2007-2012       Case-control   Retrospective   PCR                PE       NR    Y
  Young         2015   Australia           307   2002-2012       Case-control   Retrospective   IHC, ISH           PE       Y     Y
  Wang          2015   USA                 356   1995-2009       Case-control   Retrospective   PCR, IHC           PE       Y     Y
  Larque        2015   Spain               45    NR              Case-control   Retrospective   PCR, IHC           FF, PE   Y     Y
  Xu            2014   China               674   2006-NR         Case-control   Prospective     IHC                FF, PE   Y     Y
  Lassen        2014   Denmark             479   1992-2012       Case-control   Retrospective   IHC                PE       Y     NR
  Chung         2014   Multicentre         181   NR              Case-control   Prospective     IHC, ISH           PE       Y     NR
  Jiang         2013   China               71    1997-2008       Case-control   Retrospective   IHC, ISH           PE       NR    NR
  Stephen       2012   USA                 79    NR              Case-control   Retrospective   PCR                PE       NR    Y
  Duray         2010   Belgium             67    2001-2007       Case-control   Retrospective   PCR, IHC           PE       Y     Y
  Morshed       2010   Poland              93    1999-2002       Case-control   Retrospective   PCR, IHC           PE       NR    Y
  Clayman       1994   USA                 78    Prior to 1989   Case-control   Retrospective   PCR                PE       NR    Y
  ------------- ------ ------------------- ----- --------------- -------------- --------------- ------------------ -------- ----- ---------

Overall, 2578 LSCC cases were included in this analysis with 413 (16.0%) cases positive for HPV with 2051 (91.6%) male. HPV rates differed greatly between regions, as is summarised in Table [2](#TAB2){ref-type="table"}. There was no difference noted in terms of OS of HPV-positive male (OR 0.63, 95% CI 0.20-1.92, p=0.41, I^2^=75%). Majority of LSCC were smokers (n=1252, 85.6%) and alcohol drinkers (n=703, 61.1%). Also, most of LSCC were well differentiated (61.2%) and only the minority were poorly differentiated (15.7%). In terms of tumor classification, there was an even spread between the grades (T1: 27.6%, T2: 22.1%, T3: 35.4, T4: 14.9%). Most of the LSCC had no regional node involvement (58.6%). Most patients were treated with the combination of radiotherapy and/or chemotherapy (42.4%), while 30.9% had surgery alone and 26.7% had surgery with chemotherapy and/or radiotherapy (Table [3](#TAB3){ref-type="table"}).

###### Breakdown of HPV Incidence Based on Region of the World

HPV - Human Papillomavirus

  --------------------------------- ------- ------ ------------- --------------
  Author                            Year    n      HPV +         HPV -
  CHINA                                                          
  Jiang                             2013    71     31 (43.7%)    40 (56.3%)
  Xu                                2014    674    33 (4.9%)     641 (95.1%)
  Wang                              2015    318    42 (13.2%)    276 ( 86.8%)
                                    Total   1063   106 (10.0%)   957 (90.0%)
  EUROPE                                                         
  Morshed                           2010    93     33 (35.5%)    60 (64.5%)
  Duray                             2010    59     44 (74.6%)    15 (25.4%)
  Lassen                            2014    479    65 (13.6%)    414 (86.4%)
  Larque                            2015    45     4 (8.9%)      41 (91.1%)
                                    Total   676    146 (21.6%)   530 (78.4%)
  NORTH AMERICA & CENTRAL AMERICA                                
  Clayman                           1994    65     30 (46.2%)    35 (53.8%)
  Stephen                           2012    77     21 (27.3%)    56 (72.7%)
  Hernandez                         2016    101    8 (7.9%)      93 (92.1%)
  Rivera-Pena                       2016    83     41 (49.4%)    42 (50.6%)
                                    Total   326    100 (30.7%)   226 (69.3%)
  OTHERS                                                         
  Chung                             2014    181    31 (17.1%)    150 (82.9%)
  Young                             2015    288    19 (6.6%)     269 (93.4%)
  Atighechi                         2016    44     11 (25.0%)    33 (75.0%)
                                    Total   513    61 (11.9%)    452 (88.1%)
  --------------------------------- ------- ------ ------------- --------------

###### Demographics of studies involved in Meta-analysis

NR -- Not Recorded.

N0 -- no nodal metastasis

N+  --- nodal metastasis

CRT --- combination of chemotherapy and/or radiotherapy.

\*median age,

  --- ------------- ------ ------------- -------------- --------- ---------- ----------- ---------- ------------ --------------------- ------------------ -------------- ------------- ------------- --------------- ----------- ------------- --------------- --------------- -----
                                                                                                                 Differentiation       Nodal Metastasis   Location       Treatment                                                                                             
      Author        Year   n             HPV +ve        HPV -ve   Mean Age   Age Range   Male (%)   Smoker (%)   Alcohol Drinker (%)   Well-Moderate      Poor           N0            N+            Supra-glottis   Glottis     Sub-glottis   Surgery alone   Surgery + CRT   CRT
      Rivera-Pena   2016   83            41             42        NR         NR          NR         NR           NR                    NR                 NR             NR            NR            NR              NR          NR            NR              NR              NR
      Hernandez     2016   101           8              93        NR         NR          NR         NR           NR                    NR                 NR             NR            NR            NR              NR          NR            NR              NR              NR
      Atighechi     2016   44            11             33        57.8       NR          90.9       NR           NR                    NR                 NR             NR            NR            NR              NR          NR            NR              NR              NR
      Young         2015   288           19             269       66\*       36-88       93.9       88.2         NR                    NR                 NR             213           94            102             180         16            NR              95              207
      Wang          2015   318           42             276       59\*       32-87       98.1       86.1         41.5                  282                36             290           28            NR              NR          NR            228             90              NR
      Larque        2015   45            4              41        65         NR          100.0      NR           NR                    17                 28             NR            NR            13              12          16            NR              NR              NR
      Xu            2014   674           33             641       NR         NR          97.0       82.9%        65.0                  NR                 NR             363           311           172             461         31            320             354             NR
      Lassen        2014   479           65             414       NR         NR          81.0       NR           NR                    NR                 NR             156           232           NR              NR          NR            NR              NR              NR
      Chung         2014   181           31             150       NR         NR          NR         NR           NR                    NR                 NR             NR            NR            126             50          5             NR              NR              NR
      Jiang         2013   71            31             40        61.6       NR          97.2       NR           NR                    60                 11             50            21            32              39          NR            32              39              NR
      Stephen       2012   77            21             56        NR         NR          75.3       94.8         97.0                  61                 15             NR            NR            28              28          1             26              NR              51
      Duray         2010   59            44             15        NR         NR          97.0       NR           NR                    66                 1              56            11            15              35          NR            67              NR              NR
      Morshed       2010   93            33             60        NR         NR          83.9       87.9         74.7                  79                 14             49            44            54              35          4             NR              NR              NR
      Clayman       1994   65            30             35        60         NR          83.1       NR           NR                    NR                 NR             NR            NR            NR              NR          NR            22              23              23
      Total         2578   413 (16.0%)   2165 (84.0%)   \-        \-         91.6        85.6       61.1         565 (84.3%)           105 (15.7%)        1177 (61.4%)   741 (38.6%)   542 (37.3%)   840 (57.7%)     73 (5.0%)   695 (44.1%)   601 (38.1%)     281 (17.8%)     
  --- ------------- ------ ------------- -------------- --------- ---------- ----------- ---------- ------------ --------------------- ------------------ -------------- ------------- ------------- --------------- ----------- ------------- --------------- --------------- -----

In terms of survival, there was no difference noted in terms of OS in the first five years post-diagnosis (Figure [2](#FIG2){ref-type="fig"}). However, from year three to five post-diagnosis, there was a significant heterogeneity noted between studies (year three: I^2^=46%, year four: I^2^=57%, year five: I^2^=66%). Similarly, there is no difference noted in DFS in the first five years post-diagnosis. There is also significant heterogeneity in third- and fifth-year post-diagnosis (year 3: I^2^=62%, year 5: I^2^=64%). Similarly, there was no significance between DFS in the context of HPV (Figure [3](#FIG3){ref-type="fig"}).
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When OS is stratified based on location, studies from China show better OS of HPV-positive LSCC in fourth and fifth-year post-diagnosis (OR=1.92, p=0.05, and OR=1.84, p=0.05 respectively) compared to North America in the same year (OR=0.63, p=0.39, and OR=0.46, p=0.48). This demonstrates a significant difference noted between the regions in fifth-year post-diagnosis (p=0.04). Looking at heterogeneity within regions, there is a significant heterogeneity noted in third- to fifth-year post-diagnosis (p=0.05, p=0.01, and p\<0.01 respectively). The results are summarised in Table [4](#TAB4){ref-type="table"}.

###### Breakdown of odds ratio (OR) of HPV-positive LSCC as compared to HPV-negative LSCC subdivided based on global regions

HPV - Human Papillomavirus

LSCC - Laryngeal Squamous Cell Carcinoma

  ------------------------- ---------------- ------ ----------- --------- ------ ------------------------
  Regions                   No. of studies   OR     95%CI       p-value   I^2^   Hetrogeneity (p-value)
  Year 1                                                                          
  China                     2                1.27   0.41-3.88   0.68      0%     0.57
  Europe                    2                1.25   0.65-2.37   0.50      0%     0.36
  N. America & C. America   4                0.97   0.18-5.18   0.97      63%    0.04\*
  Others                    3                2.24   0.78-6.48   0.14      0%     0.93
  Between Subgroups                                             0.78      6%     0.38
  Year 2                                                                          
  China                     2                2.14   0.83-5.49   0.11      0%     0.47
  Europe                    2                0.61   0.09-3.96   0.61      68%    0.08
  N. America & C. America   4                0.96   0.32-2.87   0.95      61%    0.05\*
  Others                    3                1.21   0.61-2.43   0.59      0%     0.85
  Between Subgroups                                             0.57      23%    0.23
  Year 3                                                                          
  China                     2                1.60   0.77-3.31   0.21      0%     0.69
  Europe                    2                0.67   0.14-3.29   0.63      59%    0.12
  N. America & C. America   4                0.62   0.17-2.20   0.46      75%    \<0.01
  Others                    3                1.07   0.44-2.57   0.89      35%    0.22
  Between Subgroups                                             0.54      46%    0.05\*
  Year 4                                                                          
  China                     2                1.92   0.99-3.73   0.05\*    0%     0.76
  Europe                    2                0.63   0.16-2.44   0.51      47%    0.17
  N. America & C. America   4                0.63   0.10-3.78   0.61      85%    \<0.01\*
  Others                    3                1.28   0.68-1.89   0.60      45%    0.16
  Between Subgroups                                             0.39      57%    0.01\*
  Year 5                                                                          
  China                     3                1.84   1.00-3.36   0.05\*    0%     0.41
  Europe                    3                0.62   0.36-1.08   0.09      5%     0.35
  N. America & C. America   3                0.46   0.06-3.86   0.48      89%    \<0.01\*
  Others                    3                1.70   0.59-4.93   0.33      52%    0.13
  Between Subgroups                                             0.04\*    66%    \<0.01\*
  ------------------------- ---------------- ------ ----------- --------- ------ ------------------------

Discussion
==========

The pathogenesis of HPV and its effect on patient treatment and survival outcomes is an area of great importance in head and neck oncology. This study evaluates the current literature with regards to the pathogenesis of HPV as it relates specifically to laryngeal cancer and suggests that unlike in oropharyngeal cancer, HPV in the larynx has little to no effect on survival outcome.

HPV consists of double-stranded DNA genomes with more than 100 genotypes, of which more than 24 genotypes are detected in head and neck cancers \[[@REF13]-[@REF17]\]. HPV produces the malignant transformation of cells by producing E6 and E7 proteins that act together to lock cells in a forward replication phase \[[@REF18]\]. As a result, HPV-positive oropharyngeal SCC (OSCC) is different to their HPV-negative counterparts, in that they have different patterns of dissemination and lower incident of metachronous primary tumors \[[@REF19]\]. This may explain why HPV-positive OSCC have better responses to chemotherapy and radiotherapy, such that the latest American Joint Committee on Cancer (AJCC) divided staging for OSCC into different categories based in HPV status in the eight edition \[[@REF20]\].

HPV has a propensity for tumorigenesis in the tonsillar crypts, which are deep recesses with a discontinuous basement membrane, and vasculature, which may explain the early propensity for lymphovascular invasion and early regional nodal spread \[[@REF21]-[@REF22]\]. This contrasts with laryngeal epithelium which is squamous epithelium with less abundant lymphatics particularly in the glottis \[[@REF21]-[@REF22]\].

While there is a large body of literature looking at HPV in oropharyngeal cancer, little research has focused on laryngeal pathology with regards to HPV. In this study, we demonstrate that there is no difference in survival in the context of OS and DFS based on HPV status. This suggests that HPV is not a significant driver of LSCC, and as such HPV status has limited clinical relevance in LSCC.

Recent meta-analysis by Ndiaye and colleagues showed HPV prevalence of LSCC is 22.1% (95% CI 16.4-28.3) while another meta-analysis demonstrated that the prevalence was 26.8% or 20.3% depending on whether PCR-testing for HPV was utilized or not \[[@REF6]-[@REF7]\]. This is lower than the incidence of HPV (45.8%; 95% CI 38.9--52.9%) in OSCC in the same study \[[@REF6]\]. This demonstrates selective uptake of HPV in oropharynx as compared to larynx, and further suggests that HPV is likely not a strong indicator of LSCC. The prevalence of LSCC in this study (16%) is lower than the two above-mentioned meta-analyses. This may represent an inherent selection bias, as only studies with survival outcome and HPV status were included. As a result, the external validity of the current literature needs to be questioned in terms of providing accurate survival data on LSCC in context of HPV.

Another explanation for the different prevalence of HPV is the heterogeneity between different regional populations. The prevalence HPV-positive LSCC of Chinese cohort is 10%, while the prevalence of the rest of the world is 20.3%. While others have shown similar heterogeneity, their reported prevalence is different to our study. Ndiaye, et al. (2014) show the prevalence of HPV is 28.3% in Asia and 18.8% in North America, while Gama, et al. (2016) show point estimate of 0.246 (95%CI: 0.201-0.298) in North America to 0.399 (95%CI: 0.323-0.479) \[[@REF6]-[@REF7]\]. The lower rates in the Chinese population may, to some extent, account for a higher smoking rate in China, compared to North America.

There was no difference noted between HPV-positive and HPV-negative LSCC in terms OS and DFS. However, there was significant heterogeneity noted in studies. As mentioned previously, the AJCC now considers HPV-positive and HPV-negative OSCC different disease entities \[[@REF20]\]. This is because HPV-positive OSCC also has better survival outcomes compared to HPV-negative OSCC \[[@REF23]-[@REF25]\]. However, the same does not seem to follow for LSCC. The difference in HPV prevalence between oropharynx and larynx is still not completely well understood and it is uncertain why HPV affects OSCC and LSCC differently \[[@REF26]\].

There is significant regional variation in LSCC survival. This is most pronounced in the fifth year post-diagnosis, where there is a significant difference between the stratified cohorts (Table [4](#TAB4){ref-type="table"}). As mentioned above, Xu, et al. attribute the low prevalence of HPV in Chinese cohorts to high rates of smoking within China which may explain the variability in terms of prevalence and survival of LSCC patients in Chinese cohort \[[@REF27]\]. Furthermore, the variability also raises the concern regarding the external validity of various studies performed across the many centers around the world and calls for investigation of the cause of this difference. More molecular and epidemiologic studies are needed to evaluate the relationship of HPV and laryngeal cancers \[[@REF26]\].

Limitations

This meta-analysis is limited by the number of studies with adequate data to allow for sub-analysis of outcomes and further multivariate analysis. There were also a limited number of studies from various regions of the world, with North American and Chinese studies accounting for most of the cohort of our meta-analysis. Further research is required to better assess survival outcome of LSCC based on HPV status.

Conclusions
===========

This is the first meta-analysis to compare HPV-positive LSCC with smoking and alcohol-related LSCC and compare survival outcomes. This is the largest laryngeal meta-analysis looking at survival outcomes in laryngeal SCC with 2578 cases. Even though the study showed heterogeneity across regions in the world, particularly North America and China, the study showed that unlike oropharyngeal squamous cell carcinoma, HPV-positive LSCC does not have a better survival outcome compared to smoking and alcohol-related LSCC.
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